A retrospective analysis of patients with bullous pemphigoid treated with methotrexate

Arch Dermatol. 2008 May;144(5):612-6. doi: 10.1001/archderm.144.5.612.


Objectives: To evaluate treatment with methotrexate in patients with bullous pemphigoid and to elucidate the reduced adverse effects compared with standard treatment with prednisone.

Design: Retrospective study (January 1, 1999-December 31, 2003).

Setting: The Department of Dermatology and Venerology, Karolinska University Hospital.

Patients: A total of 138 consecutive patients with bullous pemphigoid were included and were grouped according to the treatment they received: methotrexate, prednisone, a combination of both, or topical glucocorticoids (for mild disease).

Result: Methotrexate was the most effective treatment, with only a few adverse effects and a tendency toward better survival rates in patients with moderate to severe disease.

Conclusion: Methotrexate is an effective and safe drug and provides an excellent treatment option in patients with bullous pemphigoid.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Glucocorticoids / adverse effects
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Methotrexate / adverse effects
  • Methotrexate / therapeutic use*
  • Middle Aged
  • Pemphigoid, Bullous / drug therapy*
  • Pemphigoid, Bullous / physiopathology
  • Prednisone / adverse effects
  • Prednisone / therapeutic use
  • Remission Induction
  • Retrospective Studies
  • Survival Analysis
  • Treatment Outcome


  • Anti-Inflammatory Agents
  • Glucocorticoids
  • Immunosuppressive Agents
  • Prednisone
  • Methotrexate